-
FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website. -
We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.
Menegitis/hepatitis B vaccine recalled
- Thread starter fretti
- Start date
Niko
Editor, Senior Moderator
Re: Menegitis/hepatitis B vaccine recalled
UPDATE 3-Merck recalls 1.2 mln doses of children's vaccines
Wed Dec 12, 2007 9:47pm EST
WASHINGTON, Dec 12 (Reuters) - Merck & Co Inc on Wednesday voluntarily recalled about 1.2 million doses of its widely used children's vaccines after quality-control checks found production equipment may not have been properly sterilized.
The vaccines protect against Hib disease (Haemophilus influenzae type b), which used to be the leading cause of bacterial meningitis in children less than 5 years old, according to the U.S. Centers for Disease Control and Prevention.
Merck said it recalled 11 lots of PedvaxHIB vaccine and two lots of its Comvax vaccine due to lack of assurance of product sterility. Both of the recalled vaccines protect against Hib and other conditions. Comvax also prevents hepatitis B.
The vaccines were manufactured in West Point, Pennsylvania, and distributed starting in April 2007. All but one lot was distributed in the United States, the company said.
"The potential for contamination of any individual vaccine is low, and, if present, the level of contamination would be low," Merck said.
Sterility tests of the vaccine lots subjected to recall did not turn up any contamination, said Merck, which added that the recall does not affect any other vaccines it manufactures.
Children who have received the affected vaccine do not need to be revaccinated because efficacy was not compromised, said Dr. Anne Schuchat, director of the CDC's National Center for Immunization and Respiratory Diseases.
She advised parents to look for signs of infection at the site of the inoculation in the days following the injection.
"After a week, you would definitely be out of the woods," Schuchat said.
Before vaccination became common, Hib struck one child out of every 200 in that age group, causing permanent brain damage in a quarter and killing 1 in 20.
The CDC has recommended that children receive Hib vaccine for nearly a decade. Fewer than 100 documented Hib cases currently are reported in the United States each year.
Health officials said they have urged Sanofi Pasteur, Sanofi-Aventis' vaccine business, to boost supplies in a bid to fill the gap caused by the recall.
The United States requires about 14 million doses annually to fully vaccinate babies and toddlers, and officials said they planned to tap vaccine stockpiles to help meet the need.
"We do expect there to be a shortage. The extent of that we're trying to find out," said the CDC's Schuchat. She added that the recall does not pose an immediate health risk because more than 90 percent of U.S. children have received the vaccine.
"We have a cushion of protection as we go into the recall," Schuchat said.
In November, Merck agreed to pay $4.85 billion to settle most claims that Vioxx, its withdrawn painkiller, caused heart attacks and strokes in thousands of users.
Shares in Whitehouse Station, New Jersey-based Merck lost 68 cents, or 1.1 percent, to close at $59.72 on the New York Stock Exchange. (Reporting by Lisa Richwine, Maggie Fox and Lisa Baertlein, Editing by Gary Hill, Richard Chang)
http://www.reuters.com/article/health-SP/idUSN129699920071213?pageNumber=2&virtualBrandChannel=0
UPDATE 3-Merck recalls 1.2 mln doses of children's vaccines
Wed Dec 12, 2007 9:47pm EST
WASHINGTON, Dec 12 (Reuters) - Merck & Co Inc on Wednesday voluntarily recalled about 1.2 million doses of its widely used children's vaccines after quality-control checks found production equipment may not have been properly sterilized.
The vaccines protect against Hib disease (Haemophilus influenzae type b), which used to be the leading cause of bacterial meningitis in children less than 5 years old, according to the U.S. Centers for Disease Control and Prevention.
Merck said it recalled 11 lots of PedvaxHIB vaccine and two lots of its Comvax vaccine due to lack of assurance of product sterility. Both of the recalled vaccines protect against Hib and other conditions. Comvax also prevents hepatitis B.
The vaccines were manufactured in West Point, Pennsylvania, and distributed starting in April 2007. All but one lot was distributed in the United States, the company said.
"The potential for contamination of any individual vaccine is low, and, if present, the level of contamination would be low," Merck said.
Sterility tests of the vaccine lots subjected to recall did not turn up any contamination, said Merck, which added that the recall does not affect any other vaccines it manufactures.
Children who have received the affected vaccine do not need to be revaccinated because efficacy was not compromised, said Dr. Anne Schuchat, director of the CDC's National Center for Immunization and Respiratory Diseases.
She advised parents to look for signs of infection at the site of the inoculation in the days following the injection.
"After a week, you would definitely be out of the woods," Schuchat said.
Before vaccination became common, Hib struck one child out of every 200 in that age group, causing permanent brain damage in a quarter and killing 1 in 20.
The CDC has recommended that children receive Hib vaccine for nearly a decade. Fewer than 100 documented Hib cases currently are reported in the United States each year.
Health officials said they have urged Sanofi Pasteur, Sanofi-Aventis' vaccine business, to boost supplies in a bid to fill the gap caused by the recall.
The United States requires about 14 million doses annually to fully vaccinate babies and toddlers, and officials said they planned to tap vaccine stockpiles to help meet the need.
"We do expect there to be a shortage. The extent of that we're trying to find out," said the CDC's Schuchat. She added that the recall does not pose an immediate health risk because more than 90 percent of U.S. children have received the vaccine.
"We have a cushion of protection as we go into the recall," Schuchat said.
In November, Merck agreed to pay $4.85 billion to settle most claims that Vioxx, its withdrawn painkiller, caused heart attacks and strokes in thousands of users.
Shares in Whitehouse Station, New Jersey-based Merck lost 68 cents, or 1.1 percent, to close at $59.72 on the New York Stock Exchange. (Reporting by Lisa Richwine, Maggie Fox and Lisa Baertlein, Editing by Gary Hill, Richard Chang)
http://www.reuters.com/article/health-SP/idUSN129699920071213?pageNumber=2&virtualBrandChannel=0